Andropause Symptoms: Drugs That Cause or Treat It

What Is Andropause and Why Does It Happen?

Andropause describes the gradual, age-related fall in testosterone that many men experience after their mid-30s, along with the cluster of symptoms that follow. Unlike menopause, the decline is slow and variable, not a single hormonal event. Total testosterone drops approximately 1 to 2% per year, and free testosterone falls faster because sex hormone-binding globulin (SHBG) rises with age.

The Physiology Behind the Decline

The hypothalamic-pituitary-gonadal (HPG) axis governs testosterone production. The hypothalamus secretes gonadotropin-releasing hormone (GnRH) in pulses, prompting the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH then signals the Leydig cells in the testes to produce testosterone. Age-related disruption can occur at any of these three levels, and most men show a mixed picture of primary and secondary hypogonadism by their 60s. A 2017 systematic review in JAMA Internal Medicine examining 4,000+ men confirmed progressive HPG dysregulation with advancing age.

Who Is Most Affected?

Men with obesity, type 2 diabetes, obstructive sleep apnea, or chronic opioid use are at the highest risk of clinically significant andropause symptoms before age 50. The European Male Aging Study (N=3,369) found that symptomatic hypogonadism affected approximately 2.1% of men aged 40 to 79, but prevalence rose steeply in men over 70 and in those with multiple comorbidities. European Male Aging Study data on PubMed.

What Are the Symptoms of Andropause?

Symptoms fall into three broad categories: sexual, physical, and psychological. Recognizing the full picture matters because men often present with only one complaint, such as fatigue, without connecting it to testosterone.

Sexual Symptoms

Low libido is the most specific symptom. Erectile dysfunction follows closely, although its presence alone is a poor predictor of hypogonadism because vascular and psychological causes are more common overall. Reduced morning erections and decreased ejaculatory volume are additional signals.

Physical Symptoms

• Decreased muscle mass and strength
• Increased visceral fat, particularly central adiposity
• Reduced bone mineral density (osteoporosis risk climbs after testosterone falls below 200 ng/dL)
• Hot flushes (reported in 10 to 20% of men with abrupt testosterone loss, e.g., after androgen deprivation therapy for prostate cancer)
• Fatigue and reduced stamina

Psychological and Cognitive Symptoms

Depression, irritability, difficulty concentrating, and reduced motivation are frequently reported. The Endocrine Society's 2018 Clinical Practice Guideline states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." That caution reflects how non-specific mood symptoms are, which makes laboratory confirmation non-negotiable before starting treatment.

Drugs That Cause or Worsen Andropause Symptoms

Several drug classes suppress testosterone either by acting on the HPG axis or by directly impairing Leydig cell function. This is one of the most under-recognized causes of symptomatic hypogonadism in men under 50.

Opioids and Opioid-Induced Androgen Deficiency (OPIAD)

Long-term opioid use is the single largest drug-related cause of andropause symptoms. Opioids suppress GnRH pulsatility at the hypothalamus, causing secondary hypogonadism with low LH and low testosterone. A meta-analysis published in the Journal of Sexual Medicine (N=11 studies, 3,905 patients) found that 21 to 86% of men on long-term opioid therapy had testosterone levels below the normal range. PubMed link for the OPIAD meta-analysis. Morphine, oxycodone, methadone, and fentanyl patch formulations carry the highest documented risk. Methadone appears particularly suppressive, possibly because of its long half-life.

Glucocorticoids

Systemic corticosteroids (prednisone, dexamethasone, methylprednisolone) suppress ACTH and reduce adrenal androgen production. Chronic use also directly inhibits gonadotropin secretion. Men on daily prednisone doses above 7.5 mg for more than 3 months should have baseline testosterone checked, especially if they report fatigue or sexual dysfunction.

GnRH Agonists and Antagonists

Leuprolide, goserelin, and degarelix are prescribed for prostate cancer to achieve androgen deprivation therapy (ADT). They produce profound hypogonadism (testosterone levels often below 50 ng/dL) as a therapeutic goal, but men experience every andropause symptom at high intensity, including hot flushes, loss of muscle, and osteoporosis. This population is not a treatment target for TRT (it would defeat the oncology purpose) but illustrates the direct link between testosterone suppression and symptom burden. FDA prescribing information for leuprolide.

Anabolic Androgenic Steroids (Post-Cycle Suppression)

Paradoxically, supraphysiologic androgen use suppresses endogenous testosterone through negative HPG feedback. After a cycle of exogenous anabolic steroids, LH and FSH can remain suppressed for weeks to months, leaving men with low testosterone and symptomatic andropause until the axis recovers. Recovery may be incomplete in long-term users. A case series on hypogonadism after anabolic steroid use on PubMed.

Antidepressants and Antipsychotics

Selective serotonin reuptake inhibitors (SSRIs) do not reliably lower testosterone, but they produce sexual side effects (reduced libido, anorgasmia, delayed ejaculation) that mimic andropause. This overlap creates diagnostic confusion.

Antipsychotics that raise prolactin (haloperidol, risperidone, olanzapine) are a distinct concern. Elevated prolactin suppresses GnRH, resulting in true secondary hypogonadism. Men on these agents with sexual or fatigue complaints should have both prolactin and testosterone measured before assuming primary andropause.

Ketoconazole and Other Enzyme Inhibitors

High-dose ketoconazole (used historically for Cushing syndrome) inhibits CYP17A1, blocking testosterone synthesis. Spironolactone, prescribed for heart failure and hyperaldosteronism, has anti-androgenic activity at the androgen receptor and can produce andropause-like symptoms without necessarily lowering total testosterone levels.

How Is Andropause Diagnosed?

Diagnosis requires both clinical symptoms and biochemical confirmation. Symptoms alone are insufficient to start TRT.

Laboratory Testing Protocol

The Endocrine Society recommends measuring total testosterone on at least two separate morning samples (drawn between 7:00 and 10:00 a.m.) before making a diagnosis. The diagnostic threshold is a total testosterone below 300 ng/dL by most U.S. Guidelines, though some men become symptomatic between 300 to 400 ng/dL, especially when SHBG is elevated and free testosterone is low. Endocrine Society 2018 Guideline on PubMed.

When total testosterone is borderline (300 to 400 ng/dL), free testosterone should be calculated using the Vermeulen equation or measured by equilibrium dialysis. SHBG, LH, FSH, prolactin, and a complete metabolic panel complete the initial workup.

Validated Symptom Questionnaires

The Aging Males' Symptoms (AMS) scale and the ADAM (Androgen Deficiency in Aging Males) questionnaire are widely used screening tools. The ADAM questionnaire carries a sensitivity of about 88% but specificity of only 60%, meaning a positive screen still requires blood work. Neither tool replaces biochemical testing.

Ruling Out Secondary Causes

Before attributing low testosterone to aging, clinicians must exclude reversible causes: pituitary adenoma (check prolactin and MRI if prolactin is elevated), hemochromatosis, obesity-related suppression, and drug-induced hypogonadism (reviewed above). Treating the underlying cause sometimes normalizes testosterone without TRT.

Treatments for Andropause Symptoms

Once a diagnosis is confirmed, treatment options range from TRT formulations to non-androgen agents and lifestyle modification. Choice depends on symptom severity, fertility goals, and comorbidities.

Testosterone Replacement Therapy (TRT): Formulations and Evidence

TRT is the most direct treatment for symptomatic confirmed hypogonadism.

Testosterone cypionate / enanthate (intramuscular). Doses of 100 to 200 mg every 1 to 2 weeks are the oldest and most cost-effective option. Peak-to-trough variability can be pronounced at the 2-week interval; weekly dosing at 100 mg reduces swings. A 2016 randomized controlled trial, the Testosterone Trials (TTrials, N=790, 12 months), published in NEJM found that TRT significantly improved sexual function, walking distance, and mood scores compared with placebo. TTrials primary publication in NEJM.

Testosterone gels (AndroGel 1% and 1.62%, Testim, Vogelxo). Applied daily to shoulders or upper arms, gels produce stable serum levels. Transfer to female partners or children through skin contact remains a real risk; hands must be washed and application sites covered before contact.

Testosterone patches (Androderm). Applied nightly to non-scrotal skin, patches deliver 2 to 4 mg/day. Skin irritation affects up to 37% of users per the prescribing label.

Testosterone pellets (Testopel). Implanted subcutaneously every 3 to 6 months, pellets provide the most pharmacokinetically stable testosterone delivery. Each pellet releases approximately 1 to 2 mg/day. Dose titration requires a minor office procedure.

Testosterone nasal gel (Natesto). 11 mg three times daily, administered intranasally. A 2015 study in JCEM (N=306) demonstrated that Natesto maintained LH and FSH levels better than transdermal formulations, making it an option for men who wish to preserve spermatogenesis while on testosterone therapy.

Oral testosterone undecanoate (Jatenzo, Tlando). FDA-approved since 2019 and 2022 respectively, these formulations avoid hepatotoxicity associated with older 17-alpha alkylated oral androgens. Jatenzo must be taken with food; dose starts at 237 mg twice daily and is adjusted based on serum levels at 3 to 4 weeks. FDA approval announcement for Jatenzo.

Clomiphene Citrate (Clomid) for Fertility-Sparing Treatment

Clomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogenic negative feedback at the hypothalamus, raising LH, FSH, and endogenous testosterone. It preserves spermatogenesis. Doses of 25 to 50 mg every other day to daily are commonly used off-label. A 2003 study in Fertility and Sterility (N=178) showed that clomiphene raised mean testosterone from 228 to 612 ng/dL over 4 months. PubMed link.

Clomiphene is the preferred first choice for men with secondary hypogonadism who want to father children, per clinical practice at many andrology centers. Men with primary testicular failure will not respond adequately.

Human Chorionic Gonadotropin (hCG)

HCG mimics LH, stimulating Leydig cells to produce testosterone and maintaining intratesticular testosterone concentrations that support sperm production. It is used as monotherapy in secondary hypogonadism or as an adjunct to TRT (typically 500 IU subcutaneously 2 to 3 times per week) to preserve testicular volume and fertility. A review in Translational Andrology and Urology (2018) covers hCG protocols in detail.

Anastrozole and Aromatase Inhibitors

In men with low testosterone combined with elevated estradiol (common in obesity, where aromatase in adipose tissue converts testosterone to estrogen), anastrozole 0.5 to 1 mg every other day can reduce aromatization and raise testosterone. This approach is most relevant as an adjunct, not a standalone treatment for andropause. Data supporting monotherapy remain limited, and the Endocrine Society does not currently recommend aromatase inhibitors as primary therapy.

Phosphodiesterase-5 Inhibitors for Erectile Dysfunction in Andropause

Sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) address erectile dysfunction but do not raise testosterone or resolve the non-sexual symptoms of andropause. They are frequently used alongside TRT. Response rates for PDE5 inhibitors in men with hypogonadism improve once testosterone is adequately replaced. A meta-analysis in the Journal of Sexual Medicine found combination TRT plus PDE5 inhibitor produced superior erectile function scores vs. Either agent alone.

Lifestyle Interventions That Raise Testosterone

Weight loss in obese men with low testosterone produces clinically meaningful increases. The T4DM trial (N=1,007) showed that intensive lifestyle intervention raised testosterone by approximately 2.5 nmol/L (72 ng/dL) more than usual care at 2 years. T4DM trial on PubMed. Resistance training, sleep optimization (testosterone is secreted predominantly during REM sleep), and reduction of alcohol intake to below 14 units per week are supported adjuncts.

Monitoring and Safety of TRT

Starting TRT without follow-up monitoring carries real risk. The Endocrine Society guideline specifies assessment at 3 to 6 months after initiation and annually thereafter.

Hematocrit and Cardiovascular Considerations

TRT raises hematocrit. A hematocrit above 54% requires dose reduction or temporary discontinuation because of erythrocytosis risk. The cardiovascular safety of TRT generated controversy following a 2010 trial (Basaria et al., NEJM, N=209) that was stopped early after a higher adverse cardiovascular event rate in the TRT arm in older men with mobility limitations. Basaria et al. 2010 in NEJM. The subsequent TTrials cardiovascular substudy found a greater progression of coronary artery plaque volume in the testosterone arm at 12 months, though event rates did not differ significantly.

The FDA added a label warning to all testosterone products in 2015 regarding venous thromboembolism and cardiovascular risk. Men with a recent myocardial infarction, stroke, or poorly controlled heart failure are generally not started on TRT until stabilized.

Prostate Safety

TRT is contraindicated in men with known or suspected prostate cancer. PSA should be checked at baseline, at 3 to 6 months, and annually. A PSA rise of more than 1.4 ng/mL in any 12-month period or a PSA above 4.0 ng/mL warrants urological consultation.

Fertility and Testicular Volume

Exogenous testosterone suppresses gonadotropins, reducing intratesticular testosterone to levels that impair spermatogenesis. Men who may want future children should be counseled before starting TRT. Adding hCG 500 IU subcutaneously three times weekly, or switching to clomiphene, are evidence-supported alternatives.

When Should You Seek Evaluation?

Men experiencing three or more of the following for at least 3 months deserve a formal evaluation: persistent fatigue unrelated to sleep quality, notable drop in sexual desire, new or worsening erectile dysfunction, loss of muscle despite consistent training, depressed mood without a clear psychosocial trigger, or central weight gain with loss of stamina. A single morning testosterone blood draw is the starting point.

Younger men (under 40) presenting with these symptoms should be evaluated promptly because drug-induced, structural, or genetic causes are more likely at that age than in men over 55.